Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.47 |
| ▸ | TDP2 | O95551 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 4/20 | 0.44 |
| ▸ | LAP3 | P28838 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24740685 | 0.86 | PNMT (0.45) | — | |
| SCHEMBL4133474 | 0.84 | USP30 (0.46) | USP30TDP2KMT2APGRLAP3 | |
| SCHEMBL4145248 | 0.81 | GRIN2B (0.51) | HTR1AHTR7 | |
| SCHEMBL4136458 | 0.79 | HRH3 (0.45) | LMNAHTR1AHTR7 | |
| SCHEMBL4141125 | 0.79 | HTR1A (0.47) | KDM4EHTR1AHTR7 | |
| SCHEMBL4139998 | 0.79 | HRH3 (0.45) | TDP2KMT2AHTR1AHTR7 | |
| SCHEMBL467693 | 0.79 | GRIN2B (0.49) | KMT2ALMNAALDH1A1 | |
| SCHEMBL4133418 | 0.78 | L3MBTL3 (0.51) | TDP2KMT2AALDH1A1KDM4E | |
| SCHEMBL4128788 | 0.77 | HRH3 (0.49) | TDP2PGR | |
| SCHEMBL4140118 | 0.77 | TDP2 (0.45) | TDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
| EP-2007749-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | Pfizer Products Inc. (US) | 2008-12-31 | — | — | EP | claimed |
| WO-2007105053-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | PFIZER PRODUCTS INC. (US) | 2007-09-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | USP30 3191/4885TDP2 2982/4885KMT2A 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.